Navigation Links
Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments
Date:5/10/2013

SAN DIEGO, May 10, 2013 /PRNewswire-USNewswire/ -- The ALS Emergency Treatment Fund (ALS-ETF) and Denovo Biomarkers (Denovo) have announced a partnership to explore using Denovo's technology to identify potential responder groups for drugs being studied in ALS patients.  This personalized medicine approach may accelerate drug development in ALS and other life-threatening disorders.

The partnership will integrate Denovo's pharmacogenomic technology into the analysis of biological samples obtained from expanded access programs (EAP's) that ALS-ETF sponsors.  By identifying genomic biomarkers that correlate with patients' responsiveness to treatment, the partners seek to identify appropriate patient subsets for the conduct of subsequent trials. 

"This exciting relationship with Denovo Biomarkers may accelerate the development of drugs for ALS and may help us provide useful information for patients and physicians," said Jess Rabourn , Managing Director of ALS-ETF.  Dr. Wen Luo , Chief Scientific Officer for Denovo Biomarkers, noted, "This partnership leverages the mission of ALS-ETF and the broad utility of our platform. We hope that our combined efforts will lead to better, more targeted treatments for ALS."

About The ALS Emergency Treatment Fund (ALS-ETF)

The ALS Emergency Treatment Fund, headquartered in San Francisco, is a nonprofit company created to provide near-term treatment options to sufferers of amyotrophic lateral sclerosis (ALS), a fatal disease that compromises patients' ability to move, speak, swallow and breathe.  ALS-ETF, under license from participating pharmaceutical companies, and as authorized by FDA, implements Expanded Access treatment programs (EAP's) for investigational products in development for ALS. ALS-ETF will also leverage data obtained via EAP's to add scientific value to the clinical development of each compound. By observing a broader spectrum of patients than those typically in registration trials, EAP's may illuminate how subgroups of ALS patients respond to treatment, at different stages of disease progression.  Visit www.alsetf.org.

About Denovo Biomarkers

Denovo Biomarkers, based in San Diego, is a privately-held biotechnology company providing novel biomarker approaches to personalized drug development. The company offers the industry's first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples. This technology is especially useful for compounds with suboptimal aggregate but heterogeneous late-stage trial results.  By identifying biomarkers correlated with patients' response to drug candidates retrospectively, Denovo enables biopharmaceutical manufacturers to design follow-on clinical trials in targeted patient populations while optimizing efficacy, safety and tolerability. Visit www.denovobiomarkers.com.

Contact: 
Jess Rabourn , The ALS Emergency Treatment Fund, jess.rabourn@alsetf.org, (415) 637-4774 
Michael Haller , Denovo Biomarkers, mhaller@denovobiomarkers.com, (858) 876-4012

 


'/>"/>
SOURCE The ALS Emergency Treatment Fund
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Guardian Announces Social Media Partnership with Senior Citizen Charity
2. VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
3. Bayer Partnership Delivers Industry-First Dose Management Offering
4. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
5. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
6. Medifast Announces International Expansion Into Mexico Through Strategic Partnership with Medix
7. Scotland-based Innova Partnerships Ltd. Opens Boston Office
8. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
9. Partnership Aims to Prevent Students from Misusing Prescription Drugs
10. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
11. Drug Delivery Technologies Show Promise of Improving Clinical Outcomes for Patients at PODD: Partnership Opportunities in Drug Delivery Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2018)... ... ... Jin Y. Kim, a leading board-certified periodontist who has dedicated his career ... periodontal disease in Chino Hills, CA, to take advantage of LANAP®, the FDA-cleared ... solutions for the estimated 48 percent of people who have some form of gum ...
(Date:12/14/2018)... ... 14, 2018 , ... Becker's Healthcare and Becker's Hospital Review ... 10th Annual Meeting April 1 to 4, 2019, at the Hyatt Regency in ... full agenda of business-focused and strategic discussions on the healthcare industry and organizational ...
(Date:12/13/2018)... ... , ... The American Board of Pathology (ABPath) and the ... award Continuing Medical Education (CME/SAM) credits to participants in ABPath CertLink®, an innovative ... educational provider for pathologists, as the accredited ACCME provider. ASCP will enter into ...
Breaking Medicine Technology:
(Date:12/13/2018)... ... December 13, 2018 , ... Evergreen Healthcare Partners is ... brings over 20 years of leadership experience in healthcare technology, consulting, project management ... strong teams and creating vibrant cultures of personal growth and development. In her ...
(Date:12/13/2018)... (PRWEB) , ... December 13, 2018 , ... ... Careers at High Schools , As part of its commitment to providing more jobs ... schools , Fellow Health Partners, Inc., a New York based medical business solutions ...
(Date:12/13/2018)... ... , ... Mediaplanet today announces the launch of this December’s issue of “Transplants: ... encouraging readers to sign up as an organ and/or whole-body donor for the 120,000 ... , One organ donor can save up to 8 lives, however, an average of ...
(Date:12/13/2018)... ... December 13, 2018 , ... The ... Bureau for presentations at hospital grand rounds, medical schools, medical conferences and other ... professionals the evidence-based training in Lifestyle Medicine—using lifestyle prescriptions as a therapeutic intervention ...
(Date:12/10/2018)... , ... December 10, 2018 , ... In the aftermath ... situation has more recently been reinforced by the Me Too movement. To redress the ... set their inner Man free and become the Men they were always meant to ...
Breaking Medicine News(10 mins):